Livzon Mabpharm to Develop Epirus Biosimilars in China
September 25, 2014 at 03:08 AM EDT
China's Livzon Mabpharm will collaborate with Epirus Biopharma of Boston to develop up to five biosimilar drugs for the China market. The first product is a Remicade biosimilar, which was recently approved in India. Livzon will develop the drug for China and Taiwan using Epirus' Scale™ manufacturing platform to produce the drug for these two markets. Livzon was a principal investor in Epirus' $36 million funding in April 2014. More details.... Stock Symbol: (NSDQ: EPRS) Share this with colleagues: // //